Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Park, S. W. Articles by Park, H. S. Search for Related Content PubMed PubMed Citation Articles by Park, S. W. Articles by Park, H. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 575-577, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.575-577.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Stability of New Carbapenem DA-1131 to Renal Dipeptidase (Dehydropeptidase I)

Sung Wook Park,¹ Jeoung Soon We,¹ Gye Won Kim,² Seong Hak Choi,² and Haeng Soon Park^1*

Department of Pharmacy, College of Pharmacy, Chonnam National University, Kwangju,¹ and Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Kyunggi-Do, Korea²

Received 7 September 2000/ Returned for modification 27 February 2001/ Accepted 4 November 2001

Top Abstract Introduction References

 
The stability of DA-1131 to renal dipeptidase (RDPase) (EC 3.4.13.19) was compared with that of imipenem and meropenem by V_max/K_m ratios as an index of the enzyme's preference for substrates. Our results showed a decreasing order of imipenem (6.24), meropenem (2.41), and DA-1131 (1.39). The biochemical evaluation of DA-1131 as the least preferred substrate of RDPase suggests its potential use as a novel ß-lactam antibiotic which may be usable without coadministration of RDPase inhibitors once its clinical suitability is proven.

Top Abstract Introduction References

 
Imipenem (N-formimidoylthienamycin), developed by Merck Sharp & Dohme, West Point, Pa., was highly effective against bacterial species resistant to most ß-lactam antibiotics with unusually high potency against gram-positive as well as gram-negative bacteria (8, 21, 23). It is degraded, though, in the kidneys of various animals, resulting in a reduced antibacterial activity. The enzyme responsible for this metabolism was shown to be renal dipeptidase (RDPase, also called renal dehydropeptidase I) (EC 3.4.13.19) located in the brush-border membrane of renal proximal tubules (8, 9, 20). Cilastatin, Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-butenoic acid, is a specific competitive inhibitor of RDPase and is well matched in its pharmacokinetic properties for coadministration with imipenem (8, 22). Therefore, imipenem is designed to be coadministered with cilastatin to suppress RDPase for its clinical use, and they are now manufactured in a 1:1 combination.

Meropenem, (-)-(4R,5S,6S)-3-[(3S,5S)-5-(dimethyl-carbamoyl)-3-pyrrolidinylthio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid, which was introduced in the late 1980s, though relatively less active against gram-positive bacteria than imipenem (1, 4, 6, 7), is stable in the presence of RDPase as judged by its V_max/K_m ratio. Thus, it is currently in clinical use without coadministration of an RDPase inhibitor.

DA-1131, (1R,5S,6S)-(2S,4S)-2-[(E)-3-methansulphonylamino-1-propenyl]-pyrrolidine-4-ylthiol-6-[(R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid, is a new carbapenem developed by the Research Laboratory at Dong-A Pharmaceutical Company, Yongin, Korea. It demonstrated a wide range of antibacterial activity against both gram-positive and gram-negative bacteria (G. W. Kim, M. S. Chang, K. W. Lee, Y. S. Chong, and J. Yang, Abstr. Annu. Meet. Korea Soc. Appl. Pharmacol., abstr. 232, 1996). It is also resistant to degradation by various bacterial ß-lactamases (S. H. Choi, G. W. Kim, J. Y. Kim, G. J. Lim, D. Y. Chung, W. B. Kim, and J. Yang, Abstr. Annu. Meet. Korea Soc. Appl. Pharmacol., abstr. 237, 1996). DA-1131 has been examined in many aspects, including pharmacokinetics under various conditions in animals (10, 12, 13, 16, 17, 18, 19), in the renal excretion mechanism (14, 15), and in nephrotoxicity-related studies (11).

We measured the kinetic parameters of imipenem, meropenem, and DA-1131 in relation to human RDPase and the RDPases of various animals to examine the stability of DA-1131 in reference to the two well-established ß-lactam antibiotics, imipenem and meropenem.

DA-1131 and meropenem were supplied by Dong-A Research Laboratory. Imipenem and cilastatin were obtained from Merck Sharp & Dohme. Human RDPase was purified to homogeneity with a 2,029-fold purification, and RDPases from animal sources were purified or partially purified according to the method previously described (24).

RDPase-catalyzed hydrolysis of imipenem, meropenem, and DA-1131 was measured in the presence and absence of cilastatin (0.15 µM) according to the method described by Kim and Campbell (9) by measuring the decrease in absorbance at 298 nm and 37°C as a function of time for 2.5 min. Substrate concentration was varied over a range of 1.25 to 3.3 mM in 3-(N-morpholino)propanesulfonic acid, pH 7.1. One microgram of purified RDPase was employed in a 250-µl reaction mixture, and 2-mm light path quartz cuvettes were used. The initial velocities are expressed as enzyme units (U) (micromoles of substrate hydrolyzed per minute) per milligram of protein with molar extinction coefficients at 298 nm for DA-1131, imipenem, and meropenem of 9.7314 x 10^-3, 9.3222 x 10^-3, and 1.0167 x 10^-2 M^-1 cm^-1, respectively. Protein concentrations were determined according to the Bradford method (2) with bovine serum albumin as the standard protein.

The Lineweaver-Burk plots of imipenem (Fig. 1A),meropenem (Fig. 1B), and DA-1131 (Fig. 1C) identified cilastatin as a competitive inhibitor of RDPase-catalyzed hydrolysis in all plots shown by the crossings at the y axes.

View larger version (15K): [in this window] [in a new window]

FIG. 1. Lineweaver-Burk plots of imipenem (A), meropenem (B), and DA-1131 (C). [I] represents the inhibitor concentration employed. Each data point represents the average of triplicate assays (mean ± standard deviation), and the lines were drawn using the least-squares fit method.

The kinetic parameters and V_max/K_m ratios are summarized in Table 1. The V_max/K_m ratio for each substrate has been used as an index of the enzyme's preference for substrates (3, 5). The V_max/K_m ratio decreased in the order of imipenem (6.24), meropenem (2.41), and DA-1131 (1.39), thus identifying DA-1131 as the least preferred substrate among the three, i.e., the most stable compound against RDPase. The relative percent ratio for DA-1131 was only 22.3% for imipenem and 57.7% for meropenem. The K_i values are 0.07 ± 0.02, 0.21 ± 0.04, and 0.35 ± 0.01 µM for imipenem, meropenem, and DA-1131, respectively. Comparable K_i values in such a close range indicate that RDPase acts upon these carbapenems within the same catalytic site (9).

View this table: [in this window] [in a new window]

TABLE 1. Kinetic parameters of imipenem, meropenem, and DA-1131 in human RDPase

The kinetic parameters of these carbapenems in relation to the RDPases of various animals were also determined, and the V_max/K_m ratios are summarized in Table 2. The V_max/K_m ratio for imipenem was lower than that for meropenem in mouse and rabbit RDPase but higher in rat, dog, and porcine RDPase. Thus, imipenem and meropenem exhibited large variations in resistance to RDPase depending on the enzyme source but the V_max/K_m ratio for DA-1131 was the lowest in all the tested animals. The V_max/K_m ratios for meropenem (0.95) and DA-1131 (0.74) in the porcine enzyme are significantly lower than for imipenem (19.75), thus suggesting far more stability in the presence of RDPase than imipenem. The relative ratios of DA-1131 to imipenem or meropenem were less than 1.0 in all the tested animals, thus showing higher resistance of DA-1131 to RDPase than to either antibiotic. Judging from the V_max/K_m ratio, the susceptibility of carbapenems to RDPase varied depending on the species (Tables 1 and 2). With imipenem, the V_max/K_m ratio for human RDPase (6.24) was the lowest while that of dog RDPase (39.02) was the highest. In the case of meropenem, the porcine RDPase (0.95) exhibited the lowest ratio and the rabbit RDPase (23.38) exhibited the highest, although the ratio for mouse RDPase (21.14) was similarly high. However, DA-1131 demonstrated the lowest ratio with porcine RDPase (0.74) and the highest ratio with dog RDPase (12.56), which was still significantly lower than that of either imipenem (39.02) or meropenem (16.46).

View this table: [in this window] [in a new window]

TABLE 2. Vmax/Km ratio for imipenem, meropenem, and DA-1131 in purified RDPase from various animals

Meropenem has been going through worldwide clinical trials since 1989, and it is now on the market as an effective ß-lactam antibiotic. One of the most prominent fortes of meropenem is in its relative stability to human RDPase; thus, it can be used alone, without coadministration of any RDPase inhibitor. DA-1131 is even more stable against RDPase than meropenem in all species tested so far, including humans, thus suggesting its high efficacy without coadministration of an RDPase inhibitor once its suitability is proven as a new antibiotic. DA-1131 is now being evaluated in preclinical studies.

 
This study was supported by the Korea Ministry of Science and Technology.

 
* Corresponding author. Mailing address: Department of Pharmacy, College of Pharmacy, Chonnam National University, Kwangju 500-757, Korea. Phone: 82 62 530-2923. Fax: 82 62 530-2949. E-mail: haspark{at}chonnam.chonnam.ac.kr..

Top Abstract Introduction References

 

1
1. Blumer, J. L. 1997. Meropenem: evaluation of a new generation carbapenem. Int. J. Microb. Agents 8:73-92.
2
2. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.[CrossRef][Medline]
3
3. Campbell, B. J., Y. D. Shih, L. J. Forrester, and W. L. Zahler. 1988. Specificity and inhibition studies of human renal dipeptidase. Biochim. Biophys. Acta 956:110-118.[CrossRef][Medline]
4
4. Edwards, J. R., P. J. Turner, C. Wannop, E. S. Withnell, A. J. Grindey, and K. Nairn. 1989. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob. Agents Chemother. 33:215-222.[Abstract/Free Full Text]
5
5. Fukasawa, M., Y. Sumita, E. T. Harabe, T. Tanio, H. Nouda, T. Kohzuke, T. Okuda, H. Matsumura, and M. Sunagawa. 1992. Stability of meropenem and effect of 1ß-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob. Agents Chemother. 36:1577-1579.[Abstract/Free Full Text]
6
6. Geiss, H. K., and G. Beck. 1998. Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18632 aerobic bacteria tested in 92 German centers. Int. J. Antimicrob. Agents 10:237-243.[CrossRef][Medline]
7
7. Jones, R. N., K. E. Aldridge, S. D. Allen, A. L. Barry, P. C. Fuchs, E. H. Gerlach, and M. A. Pfaller. 1989. Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob. Agents Chemother. 33:562-565.[Abstract/Free Full Text]
8
8. Kahan, F. M., H. Kropp, J. G. Sundelof, and J. Birnbaum. 1983. Thienamycin: development of imipenen-cilastatin. J. Antimicrob. Chemother. 12(Suppl. D):1-35.[Free Full Text]
9
9. Kim, H. S., and B. J. Campbell. 1982. ß-Lactamase activity of renal dipeptidase against N-formimidoyl-thienamycin. Biochem. Biophys. Res. Commun. 108:1638-1642.[CrossRef][Medline]
10
10. Kim, S. H., W. B. Kim, J. W. Kwon, and M. G. Lee. 1997. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rabbits with endotoxin-induced pyrexia. Res. Commun. Pharmacol. Toxicol. 2:121-128.
11
11. Kim, S. H., W. B. Kim, J. W. Kwon, and M. G. Lee. 1999. Nephroprotective effect of betamipron on a new carbapenem, DA-1131, in rabbits. Biopharm. Drug Dispos. 20:125-129.[CrossRef][Medline]
12
12. Kim, S. H., W. B. Kim, and M. G. Lee. 1998. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm. Drug Dispos. 19:231-235.[CrossRef][Medline]
13
13. Kim, S. H., W. B. Kim, and M. G. Lee. 1998. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus. Biopharm. Drug Dispos. 19:303-308.[CrossRef][Medline]
14
14. Kim, S. H., W. B. Kim, and M. G. Lee. 1998. No effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in dogs. Res. Commun. Mol. Pathol. Pharmacol. 101:85-92.[Medline]
15
15. Kim, S. H., W. B. Kim, and M. G. Lee. 1999. Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits. Antimicrob. Agents Chemother. 43:96-99.[Abstract/Free Full Text]
16
16. Kim, S. H., W. B. Kim, and M. G. Lee. 1999. Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats. Drug Metab. Dispos. 27:710-716.[Abstract/Free Full Text]
17
17. Kim, S. H., J. W. Kwon, W. B. Kim, and M. G. Lee. 1999. Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. Antimicrob. Agents Chemother. 43:2524-2527.[Abstract/Free Full Text]
18
18. Kim, S. H., J. W. Kwon, and M. G. Lee. 1998. Pharmacokinetics and tissue distribution of a new carbapenem DA-1131, after intravenous administration to mice, rats, rabbits and dogs. Biopharm. Drug Dispos. 19:219-229.[CrossRef][Medline]
19
19. Kim, S. H., H. J. Shim, W. B. Kim, and M. G. Lee. 1998. Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure. Antimicrob. Agents Chemother. 42:1217-1221.[Abstract/Free Full Text]
20
20. Kropp, H., J. G. Sundelof, R. Hajdu, and F. M. Kahan. 1982. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob. Agents Chemother. 22:62-70.[Abstract/Free Full Text]
21
21. Kropp, H., J. G. Sundelof, J. S. Kahan, F. M. Kahan, and J. Birnbaum. 1980. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob. Agents Chemother. 17:993-1000.[Abstract/Free Full Text]
22
22. Marier, R. L., R. V. McCloskey, G. Dickenson, C. V. Sanders, K. E. Aldridge, T. Hoffman, D. Gutterman, and A. Janney. 1983. Comparative clinical trial of imipenem-cilastatin (N-formimidoyl-thienamycin-dehydropeptidase inhibitor) and cefazolin. J. Antimicrob. Chemother. 12(Suppl. D):133-139.[Abstract/Free Full Text]
23
23. Michael, P. R., R. H. Alford, and Z. A. McGee. 1981. Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 20:702-741.[Abstract/Free Full Text]
24
24. Park, H. S., D. H. Kim, H. S. Kwark, S. K. Park, S. K. Kang, B. H. Chung, and G. S. Yoo. 1993. Human renal dipeptidase from kidneys of renal stone patients: partial purification. Arch. Pharm. Res. 16:295-299.

---

Antimicrobial Agents and Chemotherapy, February 2002, p. 575-577, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.575-577.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Park, S. W. Articles by Park, H. S. Search for Related Content PubMed PubMed Citation Articles by Park, S. W. Articles by Park, H. S.